Drug Profile


Alternative Names: ICS/LABA/LAMA inhaled triple therapy - Novartis; QVM 149

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Corticosteroids; Glucocorticoids; Indans; Pregnadienediols; Pyrrolidines; Quaternary ammonium compounds; Quinolones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma

Most Recent Events

  • 27 Feb 2017 Novartis plans a phase II trial for Asthma (NCT03063086)
  • 05 Oct 2015 Novartis plans a phase III trial for Asthma in Estonia, Germany, Lithuania and Thailand (NCT02571777)
  • 18 Jun 2015 Early research in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top